Stop Skyrocketing Drug Prices: A Briefing on Patents and Drug Prices
RSVP today to join us!
Featuring
Patricia Kelmar, Senior Director, Health Care Campaigns, Public Interest Research Group
Wayne Brough, Resident Senior Fellow, Technology and Innovation, R Street Institute
Tahir Amin, Chief Executive Officer, Initiative for Medicines, Access, and Knowledge
Christy Robinson, Principal, Matrix Global Advisors
Overview
Join the R Street Institute and the U.S. Public Interest Research Group for an important discussion on how to lower drug prices by reining in pharmaceutical industry tactics that block access to lower-cost generic alternatives. This isn’t just about policy—it’s about people. Our expert panelists will discuss reforms designed to ensure patents genuinely promote progress and innovation rather than simply extending monopolies that keep drug prices artificially high.
Lunch will be served. RSVP by July 28 to secure your spot!
Key Discussion Points
- Patents and Your Pocketbook: Learn about the fundamentals of patents and their impact on drug pricing.
- The Problem with Patent Abuse: Discover how the current patent system fails to foster innovation and improve social welfare, serving entrenched interests to protect monopoly gains instead.
- Tactics That Kill Competition: Understand pharmaceutical business practices that deter lower-cost drugs from entering the market.
- Real-World Impact: See examples of why patients, employers, and government programs are paying more due to strategies like “patent thickets” and “product hopping.”
- Game-Changing Solutions: Explore concrete, actionable solutions to bring about lower prices without compromising quality or safety.